View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; March 25, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from March 18, 2024 to March 22, 2024:  Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)     March 18, 2024XCSE7,7532,051.78  CEUX6,7572,052.57  AQEU7512,054.8...

 PRESS RELEASE

Completion of share buy-back program

Completion of share buy-back program Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.  The share buy-back program was expected to be completed no later than March 15, 2024, and comprised up to 190,000 shares.  The following transactions were executed under the program from March 11 to March 15, 2024:  No. of sharesAverage price...

 PRESS RELEASE

Genmab Announces Initiation of Share Buy-Back Program

Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to DKK 3.5 billion worth of sharesCompletion expected no later than December 16, 2024 COPENHAGEN, Denmark; March 15, 2024 – (Nasdaq: GMAB) announced today that it is initiating a share buy-back program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Time frame The share buy-back program will start on Marc...

 PRESS RELEASE

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; March 13, 2024 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf t...

 PRESS RELEASE

Constitution of the Board of Directors in Genmab A/S, Grant of Restric...

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; March 13, 2024 – (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 13, 2024, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 12,847 restricted stock units to members of the Board of Directors and employees of the Company and the Comp...

 PRESS RELEASE

Passing of Genmab A/S’ Annual General Meeting

Passing of Genmab A/S’ Annual General Meeting Company Announcement At Genmab A/S’ Annual General Meeting held today March 13, 2024, the Annual Report for 2023 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2023 Compensation Report was approvedSix members of the Board of Directors were re-electedDeloitte was elected as the new auditor of the CompanyThe proposal from the Board of Directors on the Board of Directors' remuneration for 2024, the proposal to adopt an indemnification scheme, the proposal on a new...

 PRESS RELEASE

Transactions in connection with share buy-back program

Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares. The following transactions were executed under the program from February 26 to March 8, 2024:  No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement14...

 PRESS RELEASE

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; March 4, 2024 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf ...

 PRESS RELEASE

Transactions in connection with share buy-back program

Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 4, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares. The following transactions were executed under the program from February 26 to March 1, 2024:  No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement84,...

 PRESS RELEASE

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; March 02, 2024 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf t...

 PRESS RELEASE

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 29, 2024 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behal...

 PRESS RELEASE

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 27, 2024 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their beh...

 PRESS RELEASE

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; February 27, 2024 – (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 7,325 shares at DKK 1,025.00,19,631 shares at DKK 1,032.00,2,473 shares at DKK 1,050.00,1,422 shares at DKK 1,161.00,40 shares at DKK 1,334.50,1,0...

 PRESS RELEASE

U.S. FDA Accepts for Priority Review the Supplemental Biologics Licens...

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma Media Release COPENHAGEN, Denmark; February 27, 2024 FDA grants Priority Review with target action date of June 28, 2024Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful treatment responses in difficult-to-treat patients with relapsed or refractory (R/R) follicular lymphoma (FL)sBLA submission demonstrates Genmab’s commitment to exploring potential utility of epc...

 PRESS RELEASE

Transactions in connection with share buy-back program

Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; February 26, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares. The following transactions were executed under the program from February 19 to February 23, 2024:  No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announc...

 PRESS RELEASE

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 23, 2024 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their beh...

 PRESS RELEASE

Grant of Restricted Stock Units to Management and Employees and Grant ...

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; February 23, 2024 – (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The vesti...

 PRESS RELEASE

Transactions in connection with share buy-back program

Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; February 19, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares. The following transactions were executed under the program from February 15 to February 16, 2024:  No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announc...

 PRESS RELEASE

Notice to Convene the Annual General Meeting of Genmab A/S

Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 13, 2024 COPENHAGEN, Denmark; February 15, 2024 – (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 13, 2024, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark.   The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed new Remuneration Policy is attached.  About Genmab Genmab is an international biotechnolog...

Rune Majlund Dahl
  • Rune Majlund Dahl

Genmab (Buy, TP: DKK2630.00) - Attractive opportunity

With Q4 revenue of DKK4,678m and operating profit of DKK1,670m, the 2023 guidance was met. Genmab has guided for 2024 revenue of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We believe investors expected higher costs in 2024, and we see upside potential to consensus peak sales for Tecvayli and Talvey. We reiterate our BUY and have raised our target price to DKK2,630 (2,600).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch